Loading clinical trials...
Loading clinical trials...
Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity
Conditions
Interventions
Semaglutide
Placebo (semaglutide)
Locations
28
Japan
Novo Nordisk Investigational Site
Adachi-ku, Tokyo, Japan
Novo Nordisk Investigational Site
Bunkyo-ku, Tokyo, Japan
Novo Nordisk Investigational Site
Chitose, Hokkaido, Japan
Novo Nordisk Investigational Site
Chuo-ku, Tokyo, Japan
Novo Nordisk Investigational Site
Chuo-ku,Tokyo, Japan
Novo Nordisk Investigational Site
Gunma, Japan
Start Date
January 21, 2019
Primary Completion Date
November 20, 2020
Completion Date
November 20, 2020
Last Updated
March 22, 2022
NCT01143454
NCT07472881
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions